{"id":201859,"date":"2024-12-18T12:25:34","date_gmt":"2024-12-18T18:25:34","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2024\/12\/car-t-based-therapies-in-lymphoma-a-review-of-current-practice-and-perspectives"},"modified":"2024-12-18T12:25:34","modified_gmt":"2024-12-18T18:25:34","slug":"car-t-based-therapies-in-lymphoma-a-review-of-current-practice-and-perspectives","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2024\/12\/car-t-based-therapies-in-lymphoma-a-review-of-current-practice-and-perspectives","title":{"rendered":"CAR T-Based Therapies in Lymphoma: A Review of Current Practice and Perspectives"},"content":{"rendered":"<p style=\"padding-right: 20px\"><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/car-t-based-therapies-in-lymphoma-a-review-of-current-practice-and-perspectives.jpg\"><\/a><\/p>\n<p>\ud83d\udcdd \u2014 Sheikh, et al.<\/p>\n<p>In this paper, the authors summarize the current practice and the latest progress of CD19 auto-CAR T cell therapy and the management of specific toxicities and discuss the place of allogeneic CAR T development in this setting.<\/p>\n<p>Full text is available \ud83d\udc47<\/p>\n<hr>\n<p>While more than half of non-Hodgkin lymphomas (NHL) can be cured with modern frontline chemoimmunotherapy regimens, outcomes of relapsed and\/or refractory (r\/r) disease in subsequent lines remain poor, particularly if considered ineligible for hematopoietic stem cell transplantation. Hence, r\/r NHLs represent a population with a high unmet medical need. This therapeutic gap has been partially filled by adoptive immunotherapy. CD19-directed autologous chimeric antigen receptor (auto-CAR) T cells have been transformative in the treatment of patients with r\/r B cell malignancies. Remarkable response rates and prolonged remissions have been achieved in this setting, leading to regulatory approval from the U.S. Food and Drug Administration (FDA) of four CAR T cell products between 2017 and 2021.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\ud83d\udcdd \u2014 Sheikh, et al. In this paper, the authors summarize the current practice and the latest progress of CD19 auto-CAR T cell therapy and the management of specific toxicities and discuss the place of allogeneic CAR T development in this setting. Full text is available \ud83d\udc47 While more than half of non-Hodgkin lymphomas (NHL) [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-201859","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/201859","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=201859"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/201859\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=201859"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=201859"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=201859"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}